

An Exploration on Trematodes and cestodes in humans



Md. Shahbaz Alam

M.Phil, Roll No: 142105

Session: 2014-15

University Department of Zoology

B.R.A Bihar University, Muzzaffarpur

DECLARATION: I ASAN AUTHOR OF THIS PAPER / ARTICLE, HEREBY DECLARE THAT THE PAPER SUBMITTED BY ME FOR PUBLICATION IN THE JOURNAL IS COMPLETELY MY OWN GENUINE PAPER. IF ANY ISSUE REGARDING COPYRIGHT/PATENT/ OTHER REAL AUTHOR ARISES, THE PUBLISHER WILL NOT BE LEGALLY RESPONSIBLE. IF ANY OF SUCH MATTERS OCCUR PUBLISHER MAY REMOVE MY CONTENT FROM THE JOURNAL WEBSITE. FOR THE REASON OF CONTENT AMENDMENT/ OR ANY TECHNICAL ISSUE WITH NO VISIBILITY ON WEBSITE/UPDATES, I HAVE RESUBMITTED THIS PAPER FOR THE PUBLICATION. FOR ANYPUBLICATION MATTERS OR ANY INFORMATION INTENTIONALLY HIDDEN BY ME OR OTHERWISE, I SHALL BE LEGALLY RESPONSIBLE. (COMPLETE DECLARATION OF THE AUTHOR AT THE LAST PAGE OF THIS PAPER/ARTICLE

Abstract

Praziquantel usage for treating human trematode and cestode infections is briefly reviewed, along with status and new concerns. Numerous studies have shown the effective use of praziquantel in the management of the majority of human-infecting trematodes and cestodes since it was originally marketed as a broadspectrum anthelmintic in 1975. The following trematode and cestode disorders are among those that are targeted for treatment: schistosomiasis, clonorchiasis, opisthorchiasis, paragonimiasis, heterophyidiasis, echinostomiasis, fasciolopsiasis, neodiplostomiasis, gymnophalloidiasis, taeniasis, diphylobothria. Praziquantel, however, is ineffective against *Fasciola hepatica* and *Fasciola gigantica* infections; thus, triclabendazole, a different medication, is required. Praziquantel also fails to effectively treat larval cestode infections, including hydatid disease and sparganosis. Praziquantel's exact mode of action is still not fully known. Along with allergic or hypersensitive responses to praziquantel treatment, there are also new issues with praziquantel therapy, such as the development of drug resistance in the treatment of *Schistosoma mansoni* and probably *Schistosoma japonicum*. Combining the usage of medications, such as praziquantel and other recently released substances like triclabendazole, artemisinins, and tribendimidine, is being tested as a means of coping with and resolving these issues.

Keywords: Praziquantel, Trematode, Cestode, Chemotherapy,

Introduction

The central or peripheral nervous system may get infected by cestodes, trematodes, and protozoa, which can result in a range of clinical symptoms and indications. With one exception, platyhelminthes, which include cestodes and trematodes, cannot survive without a host. All around the globe, platyhelminthes may infect the nervous system. Cestodes, sometimes known as "tapeworms," may be found in adult or larval stages. Cestodes are segmented worms with a ribbon-like form and an anterior scolex utilised for host attachment. Because adult forms seldom extend outside the gastrointestinal tract, larval forms are often more harmful to the human neurological system. This issue of *Seminars in Neurology* has an essay on neurocysticercosis, which may be the most widespread cause of epilepsy worldwide and is brought on by the cestode *Taenia solium*.

Trematodes, often known as "flukes," may subsequently enter the neurological system after infecting the liver, lungs, gastrointestinal tract, or blood. All species save *Schistosoma* are hermaphrodites, meaning they can reproduce and survive within their hosts. Trematodes have two anterior suckers that allow for a secure bond with their host. Protozoans may either be free-living organisms or obligatory parasites, depending on how they move. The range of clinical symptoms and indications of protozoal infection is broad, and nervous system infection may happen independently of other system involvement. Protozoans are often simpler to recognise by straightforward light microscopy than other parasites because of their huge size.

Cestodes

Echinococcus (Hydatid Disease)

Epidemiology

Echinococcus granulosus and *Echinococcus multilocularis* are the two species that infect humans most often. 1 Cystic echinococcosis (cystic hydatid illness) is brought on by the endemic *E. granulosus*, which is found in the Mediterranean, the Middle East, and Latin America. Alveolar echinococcosis, also known as alveolar hydatid disease, is caused by *E. multilocularis*, which is about half as big as *E. granulosus* and native to Alaska, central Europe, Turkey, and China. 1 The main hosts are red and Arctic foxes, although domestic cats and dogs may also get the disease. According to epidemiological evidence, *E. multilocularis* may spread between dogs, foxes, and rodents. 3 Because they come into touch with diseased animals more often, females and children suffer disproportionately in endemic nations.

Pathophysiology

Dogs and other canids' digestive tracts are home to *E. granulosus*. Following ingestion by a canid, the parasite swiftly moves from the small intestine to the liver before passing via blood or lymphatic arteries and into the lung, brain, vertebrae, pericardium, kidney, or periorbital tissue. As intermediary hosts, man and sheep get sick when they consume eggs shed by infected animals. Hydatid cysts with scolices-rich serous fluid develop in humans as a consequence of infection.

Solitary hydatid cysts develop in the liver as a consequence of most infections. While *E. multilocularis* may also spread by blood or lymphatic channels to other organs, it seldom affects organs other than the liver, unlike *E. granulosus*.

Trematodes

Paragonimus

Epidemiology

The only mammalian lung fluke that may infect people is *Paragonimus* spp. Globally, an estimated 20 million individuals are affected, with 10 million of them being in China. *P. westermani*, sometimes known as the "Oriental Lung Fluke," is indigenous to Western Africa and Asia and is the subspecies most frequently associated with human infection. Infection prevalence is somewhat greater in girls than in men, peaking in adolescence. The most frequent source of human *Paragonimus* spp. infection is freshwater crab or crayfish ingestion. Crabs and crayfish that have been fully cooked cannot spread disease, but many regional recipes that are pickled or marinated rather than fully cooked have the potential to do so. Other animals that may carry the fluke and spread sickness to people include domesticated cats, dogs, wild boars, and pigs.

Pathophysiology

Fluke metacercariae are discharged into the small intestine after the organism has been consumed. The larvae move through the peritoneum and intestinal wall during the course of 2 to 8 weeks in order to infiltrate the lung parenchyma. The larvae stay in the lungs until they reach adulthood, after which they migrate again. Worms in adulthood may live up to 20 years. Migration to the brain is challenging, and the method is unclear. According to some research, larvae move via the jugular vein's loose connective tissue before entering the posterior circulation through the skull base foramina. This notion is supported by the occipital and temporal lobes' propensity for infection.

Conclusion

A safe, highly effective, and broad-spectrum anthelmintic, praziquantel treats trematode and cestode infections in both people and animals. The only infections in humans for which it cannot be used are fascioliasis, hydatid disease, and sparganosis; in each of these cases, triclabendazole, a medication made up of the antibiotics praziquantel and albendazole, and surgical removal of parasites, may be used instead. Emerging issues include praziquantel-resistant *S. mansoni* and *S. japonicum* strains or isolates in the lab or in the field. Another new issue is that praziquantel medication might cause allergic, hypersensitive, or anaphylactic responses in certain individuals.

References

1. Bunnag D, Harinasuta T. Studies on the chemotherapy of human opisthorchiasis: III. Minimum effective dose of praziquantel. *Southeast Asian J Trop Med Public Health*. 1981;12:413–417.
2. Bunnag D, Radomyos P, Harinasuta T. Field trial on the treatment of fasciolopsiasis with praziquantel. *Southeast Asian J Trop Med Public Health*. 1983;14:216–219. [PubMed] [Google Scholar]
3. Chai JY, Han ET, Park YK, Guk SM, Lee SH. *Acanthoparyphium tyosenense*: the discovery of human infection and identification of its source. *J Parasitol*. 2001;87:794–800.
4. Chai JY, Nam HK, Kook J, Lee SH. The first discovery of an endemic focus of *Heterophyes nocens* (Heterophyidae) infection in Korea. *Korean J Parasitol*. 1994;32:157–161.
5. Chan JD, Zarowiecki M, Marchant JS. Ca(2+) channels and Praziquantel: A view from the free world. *Parasitol Int*. 2012;pii: S1383-5769(12)00161-4.
6. Farag HF, Ragab M, Salem A, Saden K. A short note on praziquantel in human fascioliasis. *J Trop Med Hyg*. 1986;89:79–80.
7. Farid Z, Kamal M, Mansour N. Praziquantel and *Fasciola hepatica* infection. *Trans R Soc Trop Med Hyg*. 1989;83:813.
8. Hong ST, Cho TK, Hong SJ, Chai JY, Lee SH, Seo BS. Fifteen human cases of *Fibricola seoulensis* infection in Korea. *Korean J Parasitol*. 1984;22:61–65.

9. Keiser J, Engels D, Büscher G, Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. *Expert Opin Investig Drugs*. 2005;14:1513–1526.
10. Keiser J, Utzinger J. Chemotherapy for major foodborne trematodes: a review. *Expert Opin Pharmacother*. 2004;5:1711–1726.
11. Lee SH, Chai JY, Lee HJ, Hong ST, Yu JR, Sohn WM, Kho WG, Choi MH, Lim YJ. High prevalence of *Gymnophalloides seoi* infection in a village on a southwestern island of the Republic of Korea. *Am J Trop Med Hyg*. 1994;51:281–285.
12. Lee SH. Large scale treatment of *Clonorchis sinensis* infections with praziquantel under field conditions. *Arzneimittelforschung*. 1984;34:1227–1230. [PubMed] [Google Scholar]
13. Lee SK, Chung NS, Ko IH, Sohn WM, Hong ST, Chai JY, Lee SH. An epidemiological survey of *Echinostoma hortense* infection in Chongsong-gun, Kyongbuk Province. *Korean J Parasitol*. 1988;26:199–206.
14. Rim HJ, Chang YS. Chemotherapeutic effect of niclofolan and praziquantel in the treatment of paragonimiasis. *Korea Univ Med J*. 1980;17:113–128.
15. Rim HJ, Park SB, Lee JS, Joo KH. Therapeutic effects of praziquantel (Embay 8440) against *Taenia solium* infection. *Korean J Parasitol*. 1979;17:67–72.
16. Rim HJ, Yoo KS. Chemotherapeutic effect of praziquantel (Embay 8440) in the treatment of clonorchiasis *sinensis*. *Korea Univ Med J*. 1979;16:459–470.
17. Seto EY, Wong BK, Lu D, Zhong B. Human schistosomiasis resistance to praziquantel in China: should we be worried? *Am J Trop Med Hyg*. 2011;85:74–82.
18. Udonsi JK. Clinical field trials of praziquantel in pulmonary paragonimiasis due to *Paragonimus uterobilateralis* in endemic populations of the Igwun Basin, Nigeria. *Trop Med Parasitol*. 1989;40:65–68. [PubMed] [Google Scholar]
19. Wegner DH. The profile of the trematocidal compound praziquantel. *Arzneimittelforschung*. 1984;34:1132–1136.
20. Zavoïkin VD, Zelia OP, Bronshteïn AM, Sokerina OA, Iarotskiï LS, Firsova RA, Mikhaïlov MM, Gerasimov IV. The procedure for the wide use of praziquantel in a complex of measures to control opisthorchiasis. 1. The tolerance and efficacy of different doses of biltricide during outpatient use in foci. *Med Parazitol (Mosk)* 1994;(3):24–27.

Author's Declaration

I as an author of the above research paper/article, hereby, declare that the content of this paper is prepared by me and if any person having copyright issue or patent or anything otherwise related to the content, I shall always be legally responsible for any issue. For the reason of invisibility of my research paper on the website/amendments /updates, I have resubmitted my paper for publication on the same date. If any data or information given by me is not correct I shall always be legally responsible. With my whole responsibility legally and formally I have intimated the publisher (Publisher) that my paper has been checked by my guide (if any) or expert to make it sure that paper is technically right and there is no unaccepted plagiarism and the entire content is genuinely mine. If any issue arise related to Plagiarism / Guide Name / Educational Qualification / Designation/Address of my university/college/institution/ Structure or Formatting/ Resubmission / Submission /Copyright / Patent/ Submission for any higher degree or Job/ Primary Data/ Secondary Data Issues, I will be solely/entirely responsible for any legal issues. I have been informed that the most of the data from the website is invisible or shuffled or vanished from the data base due to some technical fault or hacking and therefore the process of resubmission is there for the scholars/students who finds trouble in getting their paper on the website. At the time of resubmission of my paper I take all the legal and formal responsibilities, If I hide or do not submit the copy of my original documents (Aadhar/Driving License/Any Identity Proof and Address Proof and Photo) in spite of demand from the publisher then my paper may be rejected or removed from the website anytime and may not be consider for verification. I accept the fact that as the content of this paper and the resubmission legal responsibilities and reasons are only mine then the Publisher (Airo International Journal/Airo National Research Journal) is never responsible. I also declare that if publisher finds any complication or error or anything hidden or implemented otherwise, my paper may be removed from the website or the watermark of remark/actuality may be mentioned on my paper. Even if anything is found illegal publisher may also take legal action against me

Md.Shahbaz Alam